Nexvet Receives FY2015 Cash Refund of $3.2M under Australian Federal Government's R&D Tax Incentive Program

Nexvet Biopharma NVET today announced receipt of US$3.2 million in cash under the Australian Federal Government's Research and Development (R&D) Tax Incentive program. This program provides a 45 percent refundable tax offset for qualifying R&D in Australia, where Nexvet conducts its drug discovery activities, including PETization™. The incentive was included as a receivable in Nexvet's June 30, 2015 Form 10-K. Nexvet also recently announced the securing of a dedicated biologics manufacturing facility in Ireland, receiving non-dilutive grant support from the Irish Government. Once operational, the 20,000 square foot facility is expected to benefit from Ireland's 25 percent tax credit on qualifying R&D expenditures. "Australia and Ireland are highly supportive environments for innovative biotech companies, which makes these countries advantageous for building our drug discovery and manufacturing operations. We will continue to leverage cost advantages and other incentives in the locations in which we operate," commented Dr. Mark Heffernan, Chief Executive Officer of Nexvet. About Nexvet (www.nexvet.com) Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!